Anti-hCD20-hIgG4
-
Cat.code:
hcd20-mab4
- Documents
ABOUT
Monoclonal human IgG4 antibody against human CD20
Anti-hCD20-hIgG4 features the constant region of the human IgG4 isotype and the variable region of rituximab.
Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes.
Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity.
Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.
Anti-hCD20-hIgG4 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
CD20
Human
ELISA, Neutralization assay, Flow cytometry, Fc interaction studies
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Flow cytometry
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hCD20-hIgG4
-
Cat code:hcd20-mab4
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
Storage:
DOCUMENTS
Documents
Technical Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz